• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    The advances in immunotherapy for hepatocellular carcinoma

    2020-12-19 04:28:14FanZhangYuminLi
    Hepatoma Research 2020年7期

    Fan Zhang, Yumin Li

    1Department of Oncology Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China.

    2Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou University Second Hospital, Lanzhou 730030, Gansu,China.

    Abstract Hepatocellular carcinoma (HCC) is one of the malignant tumors with higher incidence and mortality worldwide.Recently, significant progress has been made in uncovering immunotherapy in HCC, for instance programmed death-1, cytotoxic T-lymphocyte antigen 4, chimeric antigen receptor T-cell therapy, T cell receptor T cell therapy,dendritic cell vaccine, and cytokine-induced killer cells. This paper reviews the advances in immunotherapy and focuses on the results of many of preclinical studies and clinical trials in the field, as well as some of the promising therapeutic strategies for HCC in the future.

    Keywords: HCC, PD-1, PD-L1, CTLA-4, CAR-T, T cell receptor, DC, CIK

    INTRODUCTION

    Hepatocellular carcinoma (HCC) was predicted to have the sixth highest incidence and the second highest mortality of malignant tumors worldwide in 2018[1]. The risk factors for HCC are closely related with lifestyle,chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, fatty liver disease, and cirrhosis[2-4].The management of HCC involves a multidisciplinary team approach, considering not only the tumor stage and patient complications but also the seriousness of damaged liver function, as most HCC treatments can aggravate the severity of disease[5]. Although surgical resection remains the cornerstone of HCC therapy,limitations are caused by high recurrence rates after surgery because HCC is often diagnosed at advanced stage[6]. Liver transplantation (LT) is the optimal treatment means for early-stage HCC, but limitations of LT are caused by organ shortage, tumor recurrences, and low-ratio eligibility. Comprehensive therapies for advanced HCC patients, such as radiotherapy, chemotherapy, interventional therapy, and targeted therapy,have been developed, but the 5-year survival rate remains low[7].Cancer immunotherapy was selected as its annual breakthrough in Science journal in 2013. Following the advancements of immunotherapy in solid tumors over the last few years, as shown by the results of immune checkpoint inhibitors (ICIs) in lung cancer, renal cell cancer and melanoma[8], in recent years, ICIs with anti-CTLA-4 antibodies and anti-PD-1/PD-1L antibodies have been utilized to treat advanced melanoma[9]. In 2018, because of the achievements in the treatment of cancer with ICIs of CTLA-4 and PD-1/PD-L1, James P.Allison and Tasuku Honjo were awarded the Nobel prize.

    Chimeric antigen receptor T-cell (CAR-T) immunotherapy has become more popular in the last decade as an antitumor therapy. Anti-CD19 CAR-T cell was approved by the FDA for treatment of subjects up to 25 years of age with B-cell acute lymphoblastic leukemia in 2017[10]. This article mainly summarizes the advances in ICIs and cellular immunotherapy for HCC.

    PD-1/PD-L1

    PD-1 is expressed on a subset of thymocytes and is upregulated on activated T cell, B cell, and myeloid cells[11]. Two ligands for PD-1 were identified in 2000 and 2001 and named PD-L1 and programmed death ligand 2 (PD-L2), respectively[12,13]. PD-L1 is mainly expressed on stationary T cells, B cells, DC, and hepatoma cells, while PD-L2 is only expressed on DC and macrophages[14-16]. In theory, the interaction of PD-1 and PD-L1 expressed on immature T cells can interfere with activation. Similarly, if PD-L1 is highly expressed on tumor cell, the ligand receptor interactions between tumor cells and activated T cells triggers the immunosuppressive response, leading to immune tolerance[17]. It provides a theoretical basis for the treatment of PD-L1 in HCC.

    It has been demonstrated that PD-L1 is overexpressed in HCC tissues; however, the results are controversial with respect to PD-L1 as predictive biomarkers for HCC[18]. Several studies have reported that the higher PD-L1 expression on tumor cell in HCC patients were related with worse prognosis and tumor recurrence,and the studies also showed PD-L1 expression on macrophages was associated with favorable survival rate[19-23]. However, two studies suggested that the expression of PD-L1 was not significantly correlated with survival outcomes in HCC[24,25]. Both soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) were prognostic factors with opposite prognostic values for HCC patients, while sPD-1 and sPD-L1 were not significantly related with PD-L1 expression in tumor[26]. However, two studies suggested plasma sPD-1 was associated with HBV activity and increased risk of HCC[27,28].

    I heard the footsteps7 on the sidewalk and the light tap on the wooden door. My lip began to quiver8, opening a new floodgate of tears, and I hid behind Brother Lu. Mom walked in first and hugged him, then looked at me with a weak smile. Her eyes were swollen9 from her own tears, and I was thankful she had not wept in front of me. And then he was there. He didn t even shake Luther s hand, just nodded as he swept by, coming to me and gathering10 me up into his strong arms, holding me close as he whispered to me, I love you. I love you, and I will love your baby, too.

    Lianget al.[29]illustrated that inhibition of PD-1 can suppress the growth of hepatoma and promote the apoptosis of hepatoma. Increased expression levels of PD-1 were detected in peripheral blood and tumor infiltrating lymphocytes (TILs) of recurrent HCC patients[30]. Blockade of PD-1 on TILs can restore antitumor effects of TILs[31]. However, sPD-1/sPD-L1 was not associated with either PD-L1 expression of tumor cell or the numbers of CD4-positive TILs and CD8-positive TILs[26]. Tumor infiltrating neutrophils as a new target of immunotherapy participate in tumor progression, while the tumor microenvironment(TME) induces impaired antitumor immunity via the modulation of PD-L1 expression on tumor infiltrating neutrophils[32]. PD-L1 was positively associated with expression of CD3 and CD8 in HCC samples[23]. PD-L1 expression on macrophages is also a prognostic factor for HCC patients, and it could activate high levels of CD8(+) cytotoxic T-lymphocyte (CTL) infiltration and immune related gene expression[21].

    Since immune checkpoint molecules are recognized as vital indicators of HCC progress, series of clinical trials with ICIs have been implemented to confirm their potential function for advanced HCC. Nivolumab was approved by the FDA as immunotherapy for advanced stage HCC in 2017[33]. The efficiency of nivolumab was observed in a Phase I/II non-comparative trial (CheckMate 040) of patients with HCC and prior sorafenib treatment[33]. Forty-eight patients were treated with nivolumab in a dose-escalation phase. Then,since nivolumab showed adequate safety and feasibility, 214 patients from 39 sites in 11 countries received nivolumab in a dose-expansion phase. The objective response rates (ORR) of nivolumab were 15% in the dose-escalation phase and 20% in the dose-expansion phase, suggesting that efficacy of nivolumab is not efficient. Twelve of 48 patients had Grade 3/4 treatment-associated adverse events. Although the study was positive in favor of anti-PD-1 treatment, it is worth corroborating the efficacy of nivolumab in a therapeutic schedule. Pre-treatment of sorafenib might potentiate the therapeutic response to subsequent treatment with nivolumab. In real-life experience from three German centers, Grade 3 treatment-associated events occurred in two patients (5.9%), and the partial response rate and stable disease rate in 34 patients with advanced HCC and nivolumab treatment were 11.8% and 23.5% in line with data from the CheckMate 040 trial[34].

    CD19 targeted CAR-T immunotherapy is an expecting therapeutic option that has shown high efficacy in treating hematologic malignancies[55]. Moreover, a great number of CAR-T cell products in solid tumors has also been investigated in preclinical and clinical studies. In 2008, Wilkieet al.[56]reported for the first time that MUC1 targeted CAR-T could significant delay tumor growth in solid tumor[56]. The basic principle of CAR-T cell therapy is the modification of T cells with CARs, so that they can identify tumor cells, and then the retransfusion of these CAR-T cells into the human body to fight against the target cells[57,58]. Several studies have found that GPC3-targeted CAR-T cell therapy can eliminate HCC cells in preclinical research[59-61]. GPC3 is a 70-kDa heparan oncofetal proteoglycans that is located on the tumor cell membrane[62]. It has been demonstrated that GPC3 is detected in HCC tissues with higher expression but not in normal tissues[63]. A Phase I trial (NCT02395250) of 13 Chinese GPC3-positive HCC patients illustrated the safety and preliminary efficacy of GPC3 CAR-T cells in 2017[64]. According to the patient’s tolerance, the preliminary analysis showed that GPC3 targeted CAR-T combined with the lymphodepleting conditioning had a certain efficacy[64]. The pre-clinical studies for dual-targeted CAR-T cells co-expressing GPC3 CARs and GPC3-specific CAR-modified T cells fusing a soluble PD1-CH3 fusion protein showed promising results[60,61].

    Pembrolizumab is also an antibody against PD-1. In a Phase II open-label non-randomized trial(KEYNOTE-224) to assess the efficacy of pembrolizumab as an alternative second-line treatment for HCC patients, the median overall survival (OS) was 12.9 months with a disease control rate of 61% and ORR of 17%[35]. Grade 3 toxicities arose in 25 (24%) of the 104 patients. Hence, pembrolizumab is temporarily approved by the FDA as a second-line therapy for advanced HCC, but it still needs to be verified by the results of more Phase III trials[36]. A Phase III randomized, double-blind trial to further assess the efficacy of pembrolizumab versus placebo in HCC patient is still ongoing (NCT02702401). A Phase II study evaluating camrelizumab for HCC patients with resistance to systemic treatment displayed ORR of 13.8% and acceptable treatment-related adverse events in Chinese advanced HCC patients[37]. In addition to monotherapy, possible multimodality therapeutic options involving ICIs are under investigation. Some research has observed that ICIs of PD-L1 in combination with sorafenib, lenvatinib, rapamycin, and histone deacetylase inhibitor may enhance therapeutic benefit[38-41].

    12. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.

    CTLA-4

    CTLA-4 downregulates activation of T cells by interacting with CD80/CD86 on the surface of DCs[42]. For naive T cell activation, CD28 on T cells provides the second activation signal by binding to CD80/CD86 on DCs[43]. CTLA-4 has a greater affinity for interacting with CD80/CD86 than CD28 so that it interferes in T cell activation[44]. Various single nucleotide polymorphisms (SNP) in CTLA-4 have been well-studied. Several studies observed that polymorphism of CTLA-4 was associated with increased susceptibility to HCC and haplotypes of CTLA-4 may affect the risk of HCC[45-48].

    In 2013, the first CTLA-4 blocking inhibitor in practical HCC treatment was tremelimumab, which displayed promising antitumor activity and acceptable safety[49]. In a clinical trial to validate efficacy of tremelimumab in patients with HCC and HCV infection, partial response rate and disease control rate were 17.6% and 76.4%, respectively[49]. Duffyet al.[50]attempted to combine tremelimumab with ablation as an expected therapeutic option for patients with advanced HCC (NCT01853618) . Five partial responses were observed in 19 patients, with median OS of 12.3 months. Tremelimumab is a human IgG2 monoclonal antibody that blocks the binding of CTLA-4 on the surface of activated T cell[51]. It has been reported that tremelimumab could induce tumor responses in a subset of patients with non-small cell lung cancer and refractory biliary tract cancer[52,53]. Tremelimumab therapy could elevate the amount of T cells in the peripheral blood and TILs, and CD4(+) PD-1(+) cells were more likely to be activated by tremelimumab[54]. An important adverse effect of tremelimumab is transaminitis, as a high proportion of reversible Grade 3/4 transaminitis was observed in both the above-mentioned studies.

    She climbed with the prince to the tops of high mountains; and although her tender feet bled so that even her steps were marked, she only laughed, and followed him till they could see the clouds beneath them looking like a flock of birds travelling to distant lands

    Preclinical data based on series of solid tumors indicate that dual immune checkpoint blockade is synergistic and leads to higher response rates and improved treatment outcomes compared to monotherapy. Most clinical data suggest that both CTLA-4 and PD-1/PD-L1 blockade a portion of HCC patients. Compared to CTLA-4 blockade, PD-1 and PD-L1 blockade showed relatively higher ORR, which could reach 10%-20%in advanced HCC patients. PD-1/PD-L1 blockade agents were more tolerable and less hepatoxic. Further studies for combined PD-1/PD-L1 and CTLA-4 blockades in HCC treatment are still expected, which may help to mitigate the adverse effects of the treatment. Immune checkpoint blockade in advanced HCC combined with other conventional ablative treatments, such as radiofrequency ablation (RFA) or microwave,TACE, chemotherapy, targeted medicine, or surgery would be the most promising approach for HCC patients. However, for unresectable advanced HCC, it is more appropriate to search for other combination strategies, such as the combination with multi-kinase inhibitors, vaccines, and oncolytic viruses, as well as dual inhibition of two immune checkpoint molecules.

    Based on current evidence, combination therapies with CTLA-4 are now an expected direction for the immunotherapy of advanced HCC patients in the future. A Phase III study (NCT03298451) of durvalumab with or without tremelimumabvs. sorafenib in patients of advanced HCC enrolled about 1,350 patients and explored two treatment schedules. Given the limited data to date, further testing of this combination is ongoing in a Phase II expansion. Most ongoing clinical trials have been designed to assess the efficiency of the combination strategies.

    CAR-T CELL THERAPY

    He stroked its feathers, and told it not to be afraid, for it was quite safe; but as he still felt its heart beating, he put it into a cage, where it soon plucked up courage to twitter and hop4 about

    α-fetoprotein (AFP) has been used not only as a biomarker for surveillance and diagnosis of HCC, but also as a target for immunotherapy[65]. In a clinical trial of 15 HCC patients who were given a subcutaneous injection of AFP-derived peptides, 1 patient had a complete response and the disease stabilized in 8 patients[66]. AFP, an intracellular/secreted protein, can generate AFP peptide-major histocompatibility complex (MHC) complexes as targets for CAR T-cell therapy for solid tumors. Liuet al.[67]detected that AFPtargeted CAR-T cells showed significant antitumor capacity in a mouse model Additionally, AFP-derived vaccines can augment the activity of ICIs, leading to deterioration of HCC.

    The experience from successful clinical studies of hematologic malignancies provides us with the understanding that, although selection of the specific antigen to avoid off-target or on-target/off-tumor toxicity is a primary task to be tackled, for HCC, the challenge of CAR-T is the need to ascertain a specific neoantigen and overcome the TME, gut microbiome, and HCC genomic features. Furthermore,the activation, proliferation, and persistence of CAR-T are more important for therapy. In addition,standardization in the production of CAR-T and achieving individualized treatment should be considered.

    No, said Snow-white, I dare not take anything. Are you afraid of poison? said the old woman; look, I will cut the apple in two pieces; you eat the red cheek, and I will eat the white. The apple was so cunningly made that only the red cheek was poisoned. Snow-white longed for the fine apple, and when she saw that the woman ate part of it she could resist no longer, and stretched out her hand and took the poisonous half. But hardly had she a bit of it in her mouth than she fell down dead24. Then the Queen looked at her with a dreadful look, and laughed aloud and said, White as snow, red as blood, black as ebony-wood! this time the dwarfs cannot wake you up again.

    TCR-T CELL THERAPY

    TCR-T cell immunotherapy, as one of the novel and effective antitumor treatment means, has been widely studied in oncotherapy. In 2011, Parkhurstet al.[68]firstly reported that human carcinoembryonic antigen(CEA)-targeted TCR-T cell therapy could induce objective regression of metastatic colorectal cancer[68]. The mechanisms of TCR-T cell therapies are similar to CAR-T immunotherapy. TCR-T therapy also modifies the autologous T cells with TCR, and then retransfusion expands TCR-T cell back into the patient to recognize and eliminate tumor cell, but the mechanisms for identifying antigens are quite different from CAR-T cell therapies[57]. The specific antigens recognized by CAR-T cell are all cell membrane antigens, while TCR-T cell can identify intracellular and cell membrane antigen peptides presented by MHC molecules[69]. In HBVrelated HCC, by performing the high-throughput TCR sequence of TILs in tumor and matched adjacent normal tissues, Linet al.[70]found that the combination of TCR repertoire overlap and TNM stage showed a better prognostic effect for HCC than TNM stage. Qasimet al.[71]firstly reported an HBV-related end-stage HCC case treated with HBV surface antigen as a target for HBV-specific TCR T cell therapy in 2015. In most HBV-related HCC, HBV integrations have been observed and can result in the expression of HCC cells[72].HCC cells comprise fragments of integrated HBV-DNA that encodes peptides, which can be identified by T cells[73]. Another trial was conducted in two advanced HCCs patients who underwent liver transplantation with HCC relapses[74]. During the one-year period of follow up, the volume of 5/6 pulmonary metastases was decreased in one patient receiving HBV-specific TCR T cell therapy[74]. Basic studies of TCR-T cells therapy with specific targets, such as HCV, AFP, and GPC, may be a promising immunotherapy strategy for HCC in the future[75-77]. With TCR-T immunotherapy, the efficacy and side effects seem to mainly depend on the quality of the specific target and the TCR structure. The primary challenge is the discovery of new targets,particularly in the promising field of neoantigens. However, it should be emphasized that neoantigens may be expressed on a subset of tumor cells due to heterogeneity of tumor cell; otherwise, it may cause immune escape.

    DENDRITIC CELL VACCINE

    DCs are powerful antigen-presenting cells that can stimulate T cells to induce antitumor activity. The infiltration of DCs in tumor tissue was closely associated to the improved clinical prognosis in HCC patients[78,79]. In 2002, Ladhamset al.[80]firstly reported two patients with end-stage HCC treated with autologous DCs vaccination co-cultured with autologous HCC antigens. The efficacy of DC vaccination loaded with tumor antigens from different sources has been investigated in clinical studies. Leeet al.[81]reported a trial which enrolled 31 advanced HCC patients receiving DC vaccine pulsed with autologous tumor lysates in 2005. They reported that rates of partial response and stable disease were 12.9% and 54.8%,respectively. A Phase II clinical trial reported disease control rate was 28% for advanced HCC patients with DC vaccination pulsed HepG2 lysate[82]. In another study of note, El Ansaryet al.[83], also using DC vaccine pulsed with HepG2 lysate, showed that DC vaccination could partially improve survival outcome. DC vaccination loaded with autologous tumor lysates or ex vivo HepG2 cell lysate were feasible and effective.

    However, the efficacy of DCs vaccination pulsed with tumor cell lysate is not satisfactory, and thus the use of specific antigen-modified DC vaccination has been attempted. Kakumuet al.[84]suggested that the depressed function of DCs is associated with pathogenesis of HCC with HBV or HCV infection. Several preclinical studies indicated that DCs infected with AFP or HBV antigen or both were effective strategies to enhance efficacy of DC-based vaccine[85-87]. GPC3-modified DCs were potent in inducing T cell proliferation and interferon (IFN)-y production[88]. Tadaet al.[89]reported a clinical effect was observed in one of the five patients receiving DC vaccination pulsed with AFP, GPC3, and MAGE-1 fusion proteins in 2012.Subsequently, a large sample study confirmed that the median time of progression of HCC patients with DC vaccination pulsed with AFP, GPC3 and MAGE-1 fusion proteins was longer than the control group(36.6 monthsvs. 11.8 months)[90].

    32. He G, Zhang H, Zhou J, Wang B, Chen Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2015;34:141.

    However, the maturation of DC was closely associated with efficacy of DC immunotherapy. The stimulatory capacity of dendritic cells from HCC patients was significantly lower than dendritic cells from liver cirrhosis tissue and normal samples[95]. Meanwhile, the numbers of CD83-positive DCs in HCC specimens were significantly lower compared with liver cirrhosis samples[96]. Therefore, it is very important to improve the maturation of DC, increase antigen source, and depress TME. Various stimuli, such as tumor necrosis factor alpha, lipopolysaccharide, IFN gamma, CD40-ligand, PEG10, IL-12, EpCAM, and HCA661, can significantly increase the stimulatory capacity of DCs[97-102]. Tumor endothelial marker 8 modified DCs could stimulate antitumor immunity by disrupting tumor vasculature, and DCs loaded with specific peptide, such as FoxM1,could significantly inhibit tumor growth and metastasis[103,104]. In addition, RFA can create an antigenic source with stimuli appropriate for maturation of DCs[105]. Regulatory T cells, producing immunosuppressive cytokine IL-10, were concentrated within HCC tissue and were inducted by local TME to interfere the differentiation and maturation of DC[7]. To overcome the immunosuppressive TME, Huet al.[106]introduced a promising vaccine candidate, which combine the DC/tumor cell fusion vaccine with nanoparticles of folate-modified chitosan carrying interferon-induced protein-10, which could effectively inhibit tumor cell proliferation and significantly reduce myeloid-derived suppressor cells in mouse immune organs.

    CIK/DC-CIK

    CIK are a subset of non-MHC-restricted T lymphocytes with immune modulatory effects and a crucial role in anti-tumor immunotherapy[107]. Several studies suggested that CIK cells co-cultured with DCs can significantly enhance antitumor efficiency[108,109]. Qiuet al.[110]reported that alpha-Gal epitope-pulsed DCCIK therapy remarkably prolonged the survival of patients with stage III primary HCC as compared to the controls (17.1 monthsvs. 10.1 months). In a retrospective study from 45 patients with metastatic HCC,median OS of DC-CIK immunotherapy plus ablation (32 months) or ablation (17.5 months) was higher than untreated group (3 months)[111]. In a propensity score-matched analysis, autologous CIK immunotherapy showed significantly longer RFS than the control group[112]. After 5-year follow-up, CIK immunotherapy show a significant reduction in the risk of recurrence or death[113]. The combination therapies DC-CIK with other therapeutic options, such as TACE, could improve the antitumor efficacy. Guoet al.[114]reported that DC-CIK therapy combined with TACE can improve the PFS but not the OS outcomes. However, TACE plus DC-CIK therapy for HCC patients is superior to TACE alone in improving median OS and PFS in a metaanalysis[115]. Zhouet al.[116]analyzed that clinical benefit rate of sorafenib combined with DC-CIK is higher than oral administration of sorafenib (88.6%vs. 41.9%) in a meta-analysis.

    To enhance the therapeutic efficacy of CIK cells, several pre-clinical studies suggested that co-culture of modified DCs, such as IL24-modified DCs, AFP-modified DCs, and GPC3-modified DCs, with CIKs can significantly promote CIKs differentiation and enhance lytic activity of CIK cells[117-119]. They provided a promising DC-CIK vaccine candidate for further clinical trials of HCC patients. Indeed, CIK or DC-CIK immunotherapies from autologous or allogeneic donors have already been extensively used in solid tumor patients. In our clinical center, we have experience with more than 100 gastric cancer patients with DC-CIK immunotherapy and have found that treatment outcomes were effective, safe, and feasible for gastric cancer patients. The standardization in the preparation and criteria of indication are progressing; several clinical trials are registered and ongoing. CIK or DC-CIK immunotherapies, combined with other antitumor agents,should be considered.

    CONCLUSION AND OUTLOOK

    Immunotherapies appear to be a promising treatment for advanced HCC. Multiple prospective studies are attempting to validate the therapy outcomes with PD-1/PD-L1 and/or CTLA-4 blockade. However, only a small proportion of HCC patients effectively respond to immunotherapies and much research is still needed. One of the future directions for immunotherapies is combination therapies with other ICIs, TKIs,vaccines, and oncolytic viruses, as well as conventional treatments in various stages of patients to improve the antitumor efficacy. In addition, it is the important to research how to elevate immunotherapy efficacy and ascertain the biomarkers of predictive therapeutic response to immunotherapy. For example, TMB has been used in several tumor types to predict therapeutic response to anti-PD-1 therapy. In the future, we expect to identify more predictive biomarker subsets which can be used to accurately evaluate the efficacy of immunotherapy.

    Aikido, my teacher had said again and again, is the art of reconciliation11. Whoever has the mind to fight has broken his connection with the universe. If you try to dominate people, you re already defeated. We study how to resolve conflict, not how to start it.

    CAR-T technology and its application has been hailed as a scientific breakthrough in the field of hematological tumors. Application of CAR-T therapy and TCR to treat HCC is expected to be a promising therapeutic method. The crucial challenge is the need to identify specific antigens; overcome the TME, gut microbiome,and HCC genomic features; and guard against adverse effects. Furthermore, the activation, proliferation,and persistence of CAR-T immunotherapy should be considered with the outcomes of treatments for HCC.In addition, standardization in the production of CAR-T and achieving individualized treatment should be considered.

    Different modifications of DC vaccine or DC-CIK therapy, such as selection of specific antigen targets and appropriate immunologic adjuvant, may elevate the effectiveness and safety in further studies. Dendritic cells lead to an increase in the naturally occurring neoantigen-specific immune response as well as the diversity of neoantigens. The combination of DC vaccination with other immunotherapies, e.g., TCR-T, may be a novel treatment modality in the future.

    There were seven of them, but one of them was flawed4. It looked as good as others, almost the size of a tennis ball, nice red fading to light green, but where the stem5 had been there was now a break that went straight down into the heart of the seed.

    Because of the heterogeneity of tumor cells and the complexity of immuno-regulatory mechanisms,multimodality therapies based on immunotherapy represent the next step in clinical antitumor efficacy,which will enable advancing the field and improving the outcomes of HCC patients.

    He had not gone far when all of a sudden he saw the church!He soon came to it, or rather to the wide and deep moat which surrounded it without a single bridge by which to cross

    It was in the spring- the season of storms. The sand from thedunes was whirled up in clouds; the sea was rough, and flocks of birds flew like clouds in the storm, screaming across the sand-hills.Shipwreck followed upon shipwreck on the reefs between Old Skagen and the Hunsby dunes.

    DECLARATIONS

    Authors’ contributions

    Planned and designed of the study: Li Y

    Searched the literature and wrote the manuscript, performed revisions, read and approved the final manuscript for publication: Zhang F, Li Y

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    The present study was supported by the National Natural Science Foundation of China (31770537),International S & T Cooperation Program of China (ISTCP) (2015DFA31650); International S & T Cooperation Program of Gansu Province (18YF1WA113).

    Conflicts of interest

    All authors declared that they have no conflicts of interest.

    Ethics approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ? The Author(s) 2020.

    REFERENCE

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

    24. Huang CY, Wang Y, Luo GY, Han F, Li YQ, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother 2017;40:323-33.

    3. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy. J Hepatol 2015;62:956-67.

    4. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019;157:1253-63.e2.

    5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.

    6. Desert R, Rohart F, Canal F, Sicard M, Desille M, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 2017;66:1502-18.

    “Come, little sister,” said the other princesses; then they entwined their arms and rose up in a long row to the surface of the water, close by the spot where they knew the prince’s palace stood

    7. Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2019;16:617-30.

    After 19 years of marriage, Steve Benson unsettled his wife, Jean, when he announced three years ago that he would no longer eat meat, for ethical12 reasons

    8. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.

    9. Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother 2019;20:1135-52.

    10. Administration UFaD. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. 2017. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm606540.htm [Last accessed on 16 Jun 2020]

    11. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765-72.

    Clinical trials of PD-1 antibodies combined with other adjuvant therapy, e.g., transarterial chemoembolization(TACE) and selective internal radiation treatment, are currently in progress. In addition, different combination regimens, which depend on understanding of the actual immune mechanisms in the various combinations,could help us select the optimal therapeutic option for advanced HCC.

    13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34.

    14. Finkelmeier F, Waidmann O, Trojan J. Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther 2018;18:1169-75.

    15. Yarchoan M, Xing D, Luan L, Xu H, Sharma RB, et al. Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.Clin Cancer Res 2017;23:7333-9.

    16. Mocan T, Sparchez Z, Craciun R, Bora CN, Leucuta DC. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1)axis in hepatocellular carcinoma: prognostic and therapeutic perspectives. Clin Transl Oncol 2019;21:702-12.

    While the Hunt could bring fertile fields, it was seen as a harbinger of death and war, and it was dangerous to be out when the Hunt was a field for one could become a member of the hunt, be hunted by it, or simply die (Berk and Spytma)

    19. Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702.

    18. Long J, Qu T, Pan XF, Tang X, Wan HH, et al. Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance. J Cancer Res Ther 2018;14:S1188-92.

    17. Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 2011;128:887-96.

    20. Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, et al. Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat 2017;49:246-54.

    The only problem with being in this class was that I was surrounded by at-risk students. These were kids who did not do well in school and didn t want to be there most of the time. Their home lives were obviously much different from mine, and they were constantly in trouble with the school and the law.

    21. Liu CQ, Xu J, Zhou ZG, Jin LL, Yu XJ, et al. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 2018;119:80-8.

    22. Chang H, Jung W, Kim A, Kim HK, Kim WB, et al. Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. Apmis 2017;125:690-8.

    23. Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, et al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res 2016;4:419-30.

    2. Tian Y, Yang B, Qiu W, Hao Y, Zhang Z, et al. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy. Nat Commun 2019;10:3391.

    25. Umemoto Y, Okano S, Matsumoto Y, Nakagawara H, Matono R, et al. Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy. J Gastroenterol 2015;50:65-75.

    26. Chang B, Huang T, Wei H, Shen L, Zhu D, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:353-63.

    27. Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, et al. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One 2014;9:e95870.

    28. Li N, Zhou Z, Li F, Sang J, Han Q, et al. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Oncotarget 2017;8:46020-33.

    When the King heard that he had to thank him alone for the victory, he raised him higher than anyone else in rank, gave him great treasures and made him the first in the kingdom

    29. Liang L, Ge K, Zhang F, Ge Y. The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice. Cell Mol Biol Lett 2018;23:58.

    30. Song B, Zhen S, Meng F. T cell inflammation profile after surgical resection may predict tumor recurrence in HBV-related hepatocellular carcinoma. Int Immunopharmacol 2016;41:35-41.

    31. Liu F, Zeng G, Zhou S, He X, Sun N, et al. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBVrelated hepatocellular carcinoma. Bull Cancer 2018;105:493-501.

    DCs pulsed with Hsp70 peptide and OK-432 can enhance efficacy of vaccine inducing T cell proliferation and CTL response[91,92]. In a clinical trial using Hsp70-DC vaccination, 2/12 patients demonstrated complete response and 5/12 patients demonstrated stable disease[93]. In our previous meta-analysis, we concluded DCbased therapy could prolong the median progression free survival (PFS) time and median OS time[94].

    33. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.

    34. Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, et al. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9.

    35. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.

    36. Marquardt JU, Saborowski A, Czauderna C, Vogel A. The changing landscape of systemic treatment of advanced hepatocellular carcinoma: new targeted agents and immunotherapies. Target Oncol 2019;14:115-23.

    37. Qin SK, Ren ZG, Meng ZQ, Chen ZD, Chai XL, et al. A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol 2018;29:viii719-20.

    38. Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother 2019;68:379-93.

    39. Li H, Li X, Liu S, Guo L, Zhang B, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 2017;66:1920-33.

    40. Chen ML, Yan BS, Lu WC, Chen MH, Yu SL, et al. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer 2014;134:319-31.

    41. Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci 2018;109:3993-4002.

    42. Butty V, Roy M, Sabeti P, Besse W, Benoist C, et al. Signatures of strong population differentiation shape extended haplotypes across the human CD28, CTLA4, and ICOS costimulatory genes. Proc Natl Acad Sci USA 2007;104:570-5.

    43. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity 2016;44:973-88.

    44. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol 2008;29:272-9.

    45. Yang J, Liu J, Chen Y, Tang W, Liu C, et al. Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: a case-control study. Medicine (Baltimore) 2019;98:e16266.

    46. Wang C, Liu W, Zhao L, Dong Z. Association of cytotoxic T-lymphocyte antigen-4 + 49A/G gene polymorphism with hepatocellular carcinoma risk in Chinese. J Cancer Res Ther 2018;14:S1117-20.

    47. Hu L, Liu J, Chen X, Zhang Y, Liu L, et al. CTLA-4 gene polymorphism +49 A/G contributes to genetic susceptibility to two infectionrelated cancers-hepatocellular carcinoma and cervical cancer. Hum Immunol 2010;71:888-91.

    48. Gu X, Qi P, Zhou F, Ji Q, Wang H, et al. +49G > A polymorphism in the cytotoxic T-lymphocyte antigen-4 gene increases susceptibility to hepatitis B-related hepatocellular carcinoma in a male Chinese population. Hum Immunol 2010;71:83-7.

    49. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.

    50. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.

    51. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77.

    52. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308.

    53. Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology 2019;69:2048-60.

    54. Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, et al. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother 2019;68:599-608.

    55. Mohty M, Gautier J, Malard F, Aljurf M, Bazarbachi A, et al. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma:current status and perspectives. Leukemia 2019;33:2767-78.

    56. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 2008;180:4901-9.

    57. Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol 2019;10:2250.

    58. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423-31.

    59. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.Clin Cancer Res 2014;20:6418-28.

    60. Chen C, Li K, Jiang H, Song F, Gao H, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66:475-89.

    61. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.

    62. Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev 2018;38:741-67.

    63. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, et al. Glypican 3 expression in human nonneoplastic, preneoplastic,and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008;129:899-906.

    64. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3 + hepatocellular carcinoma (r/r GPC3 + HCC). J Clin Oncol 2017;35:3049.

    65. He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy 2014;6:725-36.

    66. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, et al. Association between high-avidity T-cell receptors, induced by α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 2017;152:1395-406.e10.

    67. Liu H, Xu Y, Xiang J, Long L, Green S, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer.Clin Cancer Res 2017;23:478-88.

    68. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.

    69. Xu Y, Yang Z, Horan LH, Zhang P, Liu L, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov 2018;4:62.

    70. Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, et al. T cell receptor repertoire profiling predicts the prognosis of HBV-associated hepatocellular carcinoma. Cancer Med 2018;7:3755-62.

    71. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.

    72. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286:533-5.

    73. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.

    74. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.

    75. Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, et al. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304.

    76. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology 2018;68:574-89.

    77. Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, et al. T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 2015;149:1042-52.

    78. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003;50:1281-4.

    79. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:293-301.

    80. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.

    81. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysatepulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.

    82. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.

    83. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, et al. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol 2013;139:39-48.

    84. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000;15:431-6.

    85. Tan XH, Zhu Q, Liu C, Liu XL, Shao XT, et al. Immunization with dendritic cells infected with human AFP adenovirus vector effectively elicits immunity against mouse hepatocellular carcinomas. Zhonghua Zhong Liu Za Zhi 2006;28:13-6.

    86. Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum Immunol 2010;71:255-62.

    87. Shi M, Qian S, Chen WW, Zhang H, Zhang B, et al. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBVassociated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. Clin Exp Immunol 2007;147:277-86.

    88. Guo DW, Zhang SY, Hou XZ, Li HW, Jiang XF, et al. Glypican3 in genetically modified human monocyte-derived dendritic cells induced specific cytotoxity against glypican3 overexpressing human hepatocellular carcinoma cells in vitro. Saudi Med J 2008;29:1235-40.

    89. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601-9.

    90. Lee JH, Lee Y, Lee M, Heo MK, Song JS, et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015;113:1666-76.

    91. Ge C, Xing Y, Wang Q, Xiao W, Lu Y, et al. Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432. Int Immunopharmacol 2011;11:2200-7.

    92. Nakamoto Y, Mizukoshi E, Kitahara M, Arihara F, Sakai Y, et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Clin Exp Immunol 2011;163:165-77.

    93. Maeda Y, Yoshimura K, Matsui H, Shindo Y, Tamesa T, et al. Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother 2015;64:1047-56.

    94. Chen C, Ma YH, Zhang YT, Zhang F, Zhou N, et al. Effect of dendritic cell-based immunotherapy on hepatocellular carcinoma: a systematic review and meta-analysis. Cytotherapy 2018;20:975-89.

    95. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999;31:323-31.

    96. Chen S, Akbar SM, Tanimoto K, Ninomiya T, Iuchi H, et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: relevance to hepatocarcinogenesis. Cancer Lett 2000;148:49-57.

    97. Iwashita Y, Goto S, Tahara K, Kawano K, Chen CL, et al. Potent stimuli combined with lipopolysaccaride and IFNgamma may improve immunotherapy against HCC by increasing the maturation and subsequent immune response of the dendritic cells. Cancer Biother Radiopharm 2003;18:1-6.

    98. Gonzalez-Carmona MA, Lukacs-Kornek V, Timmerman A, Shabani S, Kornek M, et al. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo. Hepatology 2008;48:157-68.

    99. Chan RC, Pang XW, Wang YD, Chen WF, Xie Y. Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells. Br J Cancer 2004;90:1636-43.

    100. Peng W, Zhao G, Ma Y, Yu H, Wang X. Dendritic cells transfected with PEG10 recombinant adenovirus elicit anti-tumor immune response in vitro and in vivo. Vaccine 2011;29:3501-6.

    101. Vogt A, Sievers E, Lukacs-Kornek V, Decker G, Raskopf E, et al. Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo. Liver Int 2014;34:447-61.

    102. Choi YJ, Park SJ, Park YS, Park HS, Yang KM, et al. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells. PLoS One 2018;13:e0190638.

    103. Yang X, Zhu H, Hu Z. Dendritic cells transduced with TEM8 recombinant adenovirus prevents hepatocellular carcinoma angiogenesis and inhibits cells growth. Vaccine 2010;28:7130-5.

    104. Su H, Li B, Zheng L, Wang H, Zhang L. Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Oncotarget 2016;7:48401-11.

    105. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008;31:271-82.

    106. Hu Z, Chen J, Zhou S, Yang N, Duan S, et al. Mouse IP-10 gene delivered by folate-modified chitosan nanoparticles and dendritic/tumor cells fusion vaccine effectively inhibit the growth of hepatocellular carcinoma in mice. Theranostics 2017;7:1942-52.

    107. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.

    108. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice. Immunol Invest 2016;45:553-65.

    109. Chen BA, Li M, Sun ZY, Li CP, Gao C, et al. Killing activity in DC and CIK co-culture against hepatocarcinoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006;14:543-6.

    110. Qiu Y, Xu MB, Yun MM, Wang YZ, Zhang RM, et al. Hepatocellular carcinoma-specific immunotherapy with synthesized alpha1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells. World J Gastroenterol 2011;17:5260-6.

    111. Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, et al. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013;19:3473-80.

    112. Yoon JS, Song BG, Lee JH, Lee HY, Kim SW, et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:a propensity score-matched analysis of real-world data. BMC Cancer 2019;19:523.

    113. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. Cancer Immunol Immunother 2019;68:23-32.

    114. Guo W, Liu L, Wu D. Dendritic cell-cytokine induced killer cell immunotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: safety and efficacy. Nan Fang Yi Ke Da Xue Xue Bao 2014;34:674-8.

    115. He G, Zheng C, Huo H, Zhang H, Zhu Z, et al. TACE combined with dendritic cells and cytokine-induced killer cells in the treatment of hepatocellular carcinoma: a meta-analysis. Int Immunopharmacol 2016;40:436-42.

    116. Zhou Z, Qin H, Weng L, Ni Y. Clinical efficacy of DC-CIK combined with sorafenib in the treatment of advanced hepatocellular carcinoma. J Buon 2019;24:615-21.

    117. Gonzalez-Carmona MA, Marten A, Hoffmann P, Schneider C, Sievers E, et al. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 2006;26:369-79.

    118. Yu X, Xia W, Zhang T, Wang H, Xie Y, et al. Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokineinduced killer cells to hepatocellular carcinoma cells. Int J Hematol 2010;92:276-82.

    119. Wang Y, Wang Y, Mu H, Liu T, Chen X, et al. Enhanced specific antitumor immunity of dendritic cells transduced with the glypican 3 gene and co-cultured with cytokine-induced killer cells against hepatocellular carcinoma cells. Mol Med Rep 2015;11:3361-7.

    亚洲国产日韩欧美精品在线观看| 亚洲精品久久国产高清桃花| 一边摸一边抽搐一进一小说| 国内久久婷婷六月综合欲色啪| 国产亚洲精品av在线| 熟女电影av网| 嫩草影视91久久| www日本黄色视频网| 露出奶头的视频| 久久午夜亚洲精品久久| 久久久精品大字幕| 麻豆成人av在线观看| 麻豆久久精品国产亚洲av| 国产精品av视频在线免费观看| 一个人免费在线观看电影| 亚洲人成伊人成综合网2020| 九九爱精品视频在线观看| 中文字幕av在线有码专区| 两个人的视频大全免费| 久久中文看片网| 日本 欧美在线| 成人鲁丝片一二三区免费| 久久久久久久久中文| 日韩中文字幕欧美一区二区| 婷婷精品国产亚洲av在线| 国产91精品成人一区二区三区| 毛片一级片免费看久久久久 | netflix在线观看网站| 22中文网久久字幕| 国产欧美日韩精品一区二区| 精品一区二区三区人妻视频| 精品午夜福利在线看| 午夜老司机福利剧场| 欧美另类亚洲清纯唯美| 亚洲经典国产精华液单| 99久久中文字幕三级久久日本| 欧美成人a在线观看| 色av中文字幕| 在线观看免费视频日本深夜| 亚洲18禁久久av| a在线观看视频网站| 在线播放国产精品三级| 不卡一级毛片| 亚洲自偷自拍三级| 99精品久久久久人妻精品| 亚洲在线自拍视频| 国产高潮美女av| 亚洲国产欧洲综合997久久,| 国产美女午夜福利| 国产伦在线观看视频一区| 国产三级在线视频| 亚洲欧美日韩卡通动漫| 国产精品永久免费网站| 亚洲中文字幕一区二区三区有码在线看| 国产精品,欧美在线| 99riav亚洲国产免费| 精品人妻一区二区三区麻豆 | 成人毛片a级毛片在线播放| 波多野结衣高清作品| 国产精华一区二区三区| 国产精品电影一区二区三区| 日本五十路高清| 欧美性猛交╳xxx乱大交人| 国产精品一区www在线观看 | 日韩欧美 国产精品| 99久久久亚洲精品蜜臀av| 精品一区二区免费观看| 99riav亚洲国产免费| 国产v大片淫在线免费观看| 日本熟妇午夜| 日日撸夜夜添| 日韩高清综合在线| 国产激情偷乱视频一区二区| 午夜影院日韩av| 深爱激情五月婷婷| 九九爱精品视频在线观看| av天堂中文字幕网| 国产精品一区二区三区四区久久| 51国产日韩欧美| 亚洲中文日韩欧美视频| 搡老岳熟女国产| 成人午夜高清在线视频| 极品教师在线视频| 欧美激情久久久久久爽电影| 国产精品免费一区二区三区在线| 午夜精品在线福利| 亚洲无线观看免费| 国产一区二区在线观看日韩| 嫩草影院入口| 大又大粗又爽又黄少妇毛片口| 1000部很黄的大片| 免费看美女性在线毛片视频| 国产v大片淫在线免费观看| 少妇高潮的动态图| 波多野结衣高清作品| 能在线免费观看的黄片| 成人永久免费在线观看视频| 国内揄拍国产精品人妻在线| 禁无遮挡网站| 免费一级毛片在线播放高清视频| 国产 一区精品| 一级毛片久久久久久久久女| 午夜爱爱视频在线播放| 国产精品亚洲美女久久久| 久久国产乱子免费精品| 日韩高清综合在线| 国产av麻豆久久久久久久| 日本免费一区二区三区高清不卡| 搡老妇女老女人老熟妇| 亚洲天堂国产精品一区在线| 午夜免费成人在线视频| 亚洲精华国产精华精| 精品久久久久久成人av| 国产午夜精品论理片| 国产爱豆传媒在线观看| 国产精品自产拍在线观看55亚洲| 欧洲精品卡2卡3卡4卡5卡区| 国产视频一区二区在线看| 精品午夜福利在线看| 国产精品一区www在线观看 | 嫩草影院入口| 欧洲精品卡2卡3卡4卡5卡区| 一个人看的www免费观看视频| 亚洲综合色惰| 国产真实乱freesex| 国产在线男女| 久久婷婷人人爽人人干人人爱| 男人的好看免费观看在线视频| 欧美一级a爱片免费观看看| 日韩人妻高清精品专区| 午夜亚洲福利在线播放| 午夜精品一区二区三区免费看| 日本免费一区二区三区高清不卡| 亚洲av第一区精品v没综合| 国产精品久久电影中文字幕| 成人av一区二区三区在线看| 91久久精品国产一区二区成人| 国产aⅴ精品一区二区三区波| 久久久久久九九精品二区国产| 极品教师在线免费播放| 男人狂女人下面高潮的视频| 亚洲中文日韩欧美视频| 欧美日韩黄片免| 深夜a级毛片| 成人国产麻豆网| 女生性感内裤真人,穿戴方法视频| www.www免费av| 亚洲av电影不卡..在线观看| netflix在线观看网站| 欧美一区二区精品小视频在线| 国产精品一及| 亚洲国产精品成人综合色| 久久99热6这里只有精品| 美女被艹到高潮喷水动态| 成年女人看的毛片在线观看| 久久婷婷人人爽人人干人人爱| 嫩草影院新地址| 在线看三级毛片| 看黄色毛片网站| 免费观看在线日韩| 国产高清激情床上av| 久久精品综合一区二区三区| 亚洲av免费高清在线观看| 成人毛片a级毛片在线播放| 亚洲国产精品sss在线观看| 国产精品爽爽va在线观看网站| 精品一区二区三区视频在线| 级片在线观看| 国产黄片美女视频| 亚洲国产精品sss在线观看| or卡值多少钱| 麻豆国产av国片精品| 又黄又爽又刺激的免费视频.| 国产黄片美女视频| 婷婷色综合大香蕉| 免费大片18禁| 久久99热6这里只有精品| 麻豆一二三区av精品| 国产免费一级a男人的天堂| 久久精品综合一区二区三区| 亚洲国产精品久久男人天堂| 人人妻,人人澡人人爽秒播| 丝袜美腿在线中文| 在线观看舔阴道视频| 久久99热这里只有精品18| 99精品久久久久人妻精品| 日本熟妇午夜| 少妇人妻一区二区三区视频| 亚洲av熟女| 亚洲第一电影网av| 国产三级在线视频| 国产精华一区二区三区| 又黄又爽又免费观看的视频| 丰满乱子伦码专区| 国产色爽女视频免费观看| 国产精品久久久久久亚洲av鲁大| 亚洲精品久久国产高清桃花| 日本熟妇午夜| 亚洲精品国产成人久久av| 亚洲美女搞黄在线观看 | 久久精品久久久久久噜噜老黄 | 毛片一级片免费看久久久久 | 久久久久久伊人网av| 免费观看人在逋| 亚洲国产色片| 精品99又大又爽又粗少妇毛片 | 美女xxoo啪啪120秒动态图| 狂野欧美白嫩少妇大欣赏| 精品久久久久久久久久免费视频| 亚洲精品一卡2卡三卡4卡5卡| 久久亚洲精品不卡| 少妇猛男粗大的猛烈进出视频 | 久久热精品热| 狂野欧美激情性xxxx在线观看| 在线免费观看不下载黄p国产 | 男女边吃奶边做爰视频| 亚洲久久久久久中文字幕| 成人av一区二区三区在线看| 国产成人影院久久av| av在线亚洲专区| 亚洲av免费在线观看| 国产美女午夜福利| 国产一级毛片七仙女欲春2| 一夜夜www| 亚洲在线自拍视频| 久久久成人免费电影| 无人区码免费观看不卡| 国产精品一区二区性色av| 校园人妻丝袜中文字幕| 中文字幕av在线有码专区| 久久久久久久久大av| 亚洲一区高清亚洲精品| 色哟哟哟哟哟哟| 美女xxoo啪啪120秒动态图| 色av中文字幕| 日韩欧美国产一区二区入口| 精品一区二区三区视频在线| 国产精品久久久久久久电影| 中文字幕熟女人妻在线| 又爽又黄无遮挡网站| 日韩,欧美,国产一区二区三区 | 熟妇人妻久久中文字幕3abv| 欧美一区二区国产精品久久精品| 亚洲美女搞黄在线观看 | 日韩中字成人| 色视频www国产| 999久久久精品免费观看国产| 最近中文字幕高清免费大全6 | 亚洲精品在线观看二区| 俺也久久电影网| 在线国产一区二区在线| 久久久久久久久久黄片| 别揉我奶头 嗯啊视频| 国产三级中文精品| 亚洲国产色片| 国产一级毛片七仙女欲春2| 欧美在线一区亚洲| 十八禁国产超污无遮挡网站| 深夜a级毛片| 亚洲最大成人手机在线| 日韩大尺度精品在线看网址| 成人三级黄色视频| 色视频www国产| 99久久久亚洲精品蜜臀av| 中亚洲国语对白在线视频| 在线播放无遮挡| 亚洲18禁久久av| 亚洲不卡免费看| 日本免费一区二区三区高清不卡| or卡值多少钱| 亚洲美女搞黄在线观看 | 嫩草影院精品99| 国产aⅴ精品一区二区三区波| 五月伊人婷婷丁香| 18禁裸乳无遮挡免费网站照片| 国产高清三级在线| 最新中文字幕久久久久| 久久草成人影院| 亚洲成人久久性| 国产高清有码在线观看视频| 看片在线看免费视频| 久久99热这里只有精品18| 桃色一区二区三区在线观看| 亚洲国产高清在线一区二区三| 乱人视频在线观看| 黄色欧美视频在线观看| 88av欧美| 最近最新中文字幕大全电影3| 男人舔女人下体高潮全视频| 男人狂女人下面高潮的视频| 自拍偷自拍亚洲精品老妇| 日本欧美国产在线视频| 欧美+日韩+精品| 88av欧美| 99精品在免费线老司机午夜| 五月伊人婷婷丁香| 干丝袜人妻中文字幕| 两个人的视频大全免费| 国产色爽女视频免费观看| av在线观看视频网站免费| 国产精品嫩草影院av在线观看 | 校园人妻丝袜中文字幕| 熟妇人妻久久中文字幕3abv| 制服丝袜大香蕉在线| 99久久精品一区二区三区| 久久精品国产清高在天天线| av黄色大香蕉| 久久精品国产清高在天天线| 日本三级黄在线观看| 精品久久久久久,| 欧美xxxx性猛交bbbb| 我的老师免费观看完整版| 高清毛片免费观看视频网站| 中文亚洲av片在线观看爽| 天天躁日日操中文字幕| 亚洲精品一卡2卡三卡4卡5卡| 狠狠狠狠99中文字幕| 久久久久免费精品人妻一区二区| 嫩草影院精品99| 精品久久久久久久人妻蜜臀av| 久久精品久久久久久噜噜老黄 | 日本熟妇午夜| 最近中文字幕高清免费大全6 | 国产黄a三级三级三级人| 中文字幕人妻熟人妻熟丝袜美| 国内揄拍国产精品人妻在线| 亚洲国产精品久久男人天堂| 草草在线视频免费看| 亚洲av电影不卡..在线观看| 日韩精品有码人妻一区| 精品久久久久久成人av| 男女做爰动态图高潮gif福利片| 一级av片app| 亚洲乱码一区二区免费版| 国产成人av教育| 欧美一区二区精品小视频在线| 精品欧美国产一区二区三| 亚洲国产高清在线一区二区三| 国模一区二区三区四区视频| 在线观看66精品国产| 欧美在线一区亚洲| 日日摸夜夜添夜夜添小说| 国产午夜精品久久久久久一区二区三区 | 极品教师在线视频| 99久久九九国产精品国产免费| 亚洲综合色惰| 一级黄片播放器| 亚洲av二区三区四区| 有码 亚洲区| 欧美另类亚洲清纯唯美| 成人毛片a级毛片在线播放| 嫩草影院新地址| 亚洲在线自拍视频| 18禁黄网站禁片免费观看直播| 国内精品宾馆在线| 内射极品少妇av片p| 波多野结衣高清作品| 极品教师在线视频| 欧美日韩黄片免| 嫩草影院新地址| 亚洲欧美日韩高清在线视频| eeuss影院久久| 能在线免费观看的黄片| 在线天堂最新版资源| 精品免费久久久久久久清纯| 国产亚洲精品综合一区在线观看| 免费大片18禁| 亚洲国产精品合色在线| 欧美成人a在线观看| 国语自产精品视频在线第100页| 69av精品久久久久久| 日韩,欧美,国产一区二区三区 | 成年女人看的毛片在线观看| 麻豆国产av国片精品| 悠悠久久av| 国产人妻一区二区三区在| 国内少妇人妻偷人精品xxx网站| 国产精品一区www在线观看 | 日本三级黄在线观看| 九九久久精品国产亚洲av麻豆| 亚洲第一电影网av| 久久中文看片网| 亚洲人成网站高清观看| 女生性感内裤真人,穿戴方法视频| 国产av麻豆久久久久久久| 国产精品日韩av在线免费观看| 小蜜桃在线观看免费完整版高清| 欧美一区二区亚洲| 成人国产综合亚洲| www.www免费av| 免费av不卡在线播放| 嫩草影院新地址| 免费av观看视频| 最近视频中文字幕2019在线8| 午夜日韩欧美国产| 国内毛片毛片毛片毛片毛片| 欧美人与善性xxx| 国产精品精品国产色婷婷| 久久久久久久久久成人| 日日干狠狠操夜夜爽| 黄色一级大片看看| 中国美女看黄片| 亚洲中文字幕日韩| 乱系列少妇在线播放| 91午夜精品亚洲一区二区三区 | 婷婷六月久久综合丁香| 国产在线精品亚洲第一网站| 变态另类丝袜制服| 免费av观看视频| 我要搜黄色片| 亚洲av二区三区四区| 99riav亚洲国产免费| 永久网站在线| 精品无人区乱码1区二区| 国产三级在线视频| 免费黄网站久久成人精品| 久久久久久伊人网av| 国产精品永久免费网站| 国产亚洲91精品色在线| 久久久久久久久中文| 亚洲av一区综合| 色综合色国产| 亚洲最大成人手机在线| 久久欧美精品欧美久久欧美| 婷婷丁香在线五月| 色吧在线观看| 国产av麻豆久久久久久久| 舔av片在线| 亚洲,欧美,日韩| 啪啪无遮挡十八禁网站| 亚洲国产高清在线一区二区三| 午夜精品久久久久久毛片777| 日韩精品青青久久久久久| 又爽又黄无遮挡网站| 日韩精品青青久久久久久| 亚洲四区av| 在线观看66精品国产| 一个人免费在线观看电影| 亚洲成av人片在线播放无| 国产亚洲91精品色在线| 老女人水多毛片| 国产亚洲91精品色在线| 搡老熟女国产l中国老女人| av视频在线观看入口| 亚洲av二区三区四区| 亚洲最大成人手机在线| 人人妻,人人澡人人爽秒播| 如何舔出高潮| 99热只有精品国产| 欧美高清成人免费视频www| а√天堂www在线а√下载| 黄色日韩在线| 欧美色视频一区免费| 久久精品人妻少妇| 蜜桃亚洲精品一区二区三区| 国产精品一及| 真人做人爱边吃奶动态| 搡老妇女老女人老熟妇| 男女做爰动态图高潮gif福利片| 亚洲男人的天堂狠狠| 免费不卡的大黄色大毛片视频在线观看 | 亚洲欧美日韩高清在线视频| 最近视频中文字幕2019在线8| 久久久久国产精品人妻aⅴ院| 国产成人影院久久av| 久久久久久九九精品二区国产| 美女高潮的动态| 男女之事视频高清在线观看| 亚洲av二区三区四区| 日韩亚洲欧美综合| 日韩欧美精品v在线| 在线播放国产精品三级| 成年女人永久免费观看视频| 亚洲欧美日韩东京热| a在线观看视频网站| 日韩人妻高清精品专区| 成人亚洲精品av一区二区| 男女做爰动态图高潮gif福利片| 亚洲人成网站在线播| 亚洲美女视频黄频| 啦啦啦韩国在线观看视频| 在线观看美女被高潮喷水网站| 亚洲精品一卡2卡三卡4卡5卡| 99在线视频只有这里精品首页| 人人妻,人人澡人人爽秒播| 又爽又黄无遮挡网站| 午夜影院日韩av| 欧美丝袜亚洲另类 | 国产精品久久电影中文字幕| 国产av不卡久久| 国产精品亚洲美女久久久| 97热精品久久久久久| 久久热精品热| 欧美日韩亚洲国产一区二区在线观看| 天堂动漫精品| 搞女人的毛片| 久久国内精品自在自线图片| 婷婷精品国产亚洲av在线| 欧洲精品卡2卡3卡4卡5卡区| 国产一区二区激情短视频| 国产免费男女视频| 给我免费播放毛片高清在线观看| 欧美日本亚洲视频在线播放| 一本精品99久久精品77| 最近视频中文字幕2019在线8| 国语自产精品视频在线第100页| 国产淫片久久久久久久久| 国产 一区精品| av在线老鸭窝| 深爱激情五月婷婷| 国产精品久久久久久久电影| 日本撒尿小便嘘嘘汇集6| 99久久精品热视频| 小蜜桃在线观看免费完整版高清| 毛片一级片免费看久久久久 | 男插女下体视频免费在线播放| 日日啪夜夜撸| 级片在线观看| 黄色视频,在线免费观看| 又紧又爽又黄一区二区| 亚洲人成伊人成综合网2020| 他把我摸到了高潮在线观看| 午夜视频国产福利| 深爱激情五月婷婷| 欧美不卡视频在线免费观看| 别揉我奶头~嗯~啊~动态视频| 五月伊人婷婷丁香| 国产探花在线观看一区二区| 欧美激情在线99| 身体一侧抽搐| 老司机福利观看| 国产精品一区二区三区四区久久| 不卡视频在线观看欧美| 精品欧美国产一区二区三| 97人妻精品一区二区三区麻豆| 亚洲在线观看片| 搡老妇女老女人老熟妇| 1000部很黄的大片| 亚洲人成网站在线播| 国产一区二区激情短视频| 亚洲色图av天堂| 别揉我奶头~嗯~啊~动态视频| 黄片wwwwww| 亚洲三级黄色毛片| 亚洲av第一区精品v没综合| 我的老师免费观看完整版| 老司机福利观看| 国产精品三级大全| 波野结衣二区三区在线| 在线免费观看不下载黄p国产 | 亚洲中文日韩欧美视频| 久久天躁狠狠躁夜夜2o2o| 人人妻,人人澡人人爽秒播| 午夜久久久久精精品| 国产精品女同一区二区软件 | 麻豆av噜噜一区二区三区| 美女高潮喷水抽搐中文字幕| 欧美激情国产日韩精品一区| 1024手机看黄色片| avwww免费| 麻豆一二三区av精品| videossex国产| 欧美日本亚洲视频在线播放| 精品久久久久久久久久免费视频| 日日干狠狠操夜夜爽| 国产爱豆传媒在线观看| 国产精品永久免费网站| 俄罗斯特黄特色一大片| 欧美日韩黄片免| 亚洲av电影不卡..在线观看| 成人特级av手机在线观看| 在线观看免费视频日本深夜| 精华霜和精华液先用哪个| 人妻丰满熟妇av一区二区三区| 欧美激情在线99| 亚洲精品亚洲一区二区| 日韩欧美国产在线观看| 偷拍熟女少妇极品色| 国内精品美女久久久久久| 精品99又大又爽又粗少妇毛片 | 精品福利观看| 真人一进一出gif抽搐免费| 人人妻,人人澡人人爽秒播| 国产久久久一区二区三区| 亚洲最大成人av| 精品一区二区三区视频在线观看免费| 亚洲av不卡在线观看| 欧美性猛交黑人性爽| 国产老妇女一区| 成年女人毛片免费观看观看9| 亚洲av成人av| 亚洲色图av天堂| aaaaa片日本免费| 五月玫瑰六月丁香| 网址你懂的国产日韩在线| 国产日本99.免费观看| 97超视频在线观看视频| 日韩精品中文字幕看吧| 午夜精品在线福利| 亚洲美女黄片视频| 精品久久久久久久久久免费视频| 日韩av在线大香蕉| 波多野结衣高清无吗| 亚洲美女搞黄在线观看 | 狠狠狠狠99中文字幕| 日韩一本色道免费dvd| 久久国产精品人妻蜜桃| 日韩av在线大香蕉| 国产男靠女视频免费网站| 亚洲av成人精品一区久久| 国产精品久久久久久av不卡| 久久人人精品亚洲av| av专区在线播放| 日本一二三区视频观看| 久久精品夜夜夜夜夜久久蜜豆|